STEVE ELMS - 27 Nov 2024 Form 4 Insider Report for ADMA BIOLOGICS, INC. (ADMA)

Role
Director
Signature
/s/ Steve Elms, by Michael A. Goldstein as Attorney-in-fact
Issuer symbol
ADMA
Transactions as of
27 Nov 2024
Transactions value $
$97,200
Form type
4
Filing time
02 Dec 2024, 21:02:40 UTC
Previous filing
17 Jun 2024
Next filing
26 Dec 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADMA Common Stock Options Exercise $97,200 +9,000 +0.43% $10.8 2,124,671 27 Nov 2024 See footnote F1
holding ADMA Common Stock 76,441 27 Nov 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADMA Stock Option (Right to Buy) Options Exercise $0 -9,000 -100% $0 0 27 Nov 2024 Common Stock 9,000 $10.8 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are owned by Aisling Capital II LP ("Aisling"), which is a fund that was established in 2007 with a 10-year life. Mr. Elms is Aisling's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC ("Aisling Partners"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP ("Aisling GP"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of Aisling's investment in the Company and Aisling Partners' ownership of the Company's options, except to the extent of his pecuniary interest therein.
F2 Includes, as of the transaction date, (i) 12,020 restricted stock units ("RSUs") granted on February 26, 2024, which will vest fully on February 26, 2025, subject to the Reporting Person's continued service as of such vesting date; and (ii) 64,421 shares of common stock owned by the Reporting Person.
F3 The Reporting Person is exercising these options due to their near-term expiration date.
F4 These options vested monthly over a period of 24 months from the date of grant, becoming fully vested on January 30, 2017.

Remarks:

Exhibit 24 - Power of Attorney